The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2015 | Immunomodulators, proteasome inhibitors and monoclonal antibodies for multiple myeloma
There is currently no standard treatment for patients with relapsed or refractory multiple myeloma. At the 20th Congress of the European Hematology Association (EHA), Pieter Sonneveld, MD, of the Erasmus MC University Cancer Institute, Rotterdam, the Netherlands, discusses promising agents for this patient population, including immunomodulatory agents, such as lenalidomide and pomalidomide; proteasome inhibitors, such as carfilzomib; and monoclonal antibodies, such as daratumumab and elotuzumab.
